Dual HER2 inhibition: Is two better than one?

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-10-11 DOI:10.1016/j.medj.2024.07.008

Matthew R Strickland, Samuel J Klempner

引用次数: 0

Abstract

Li et al. present data from a randomized frontline phase II trial in HER2+ gastroesophageal cancers exploring dual targeting of HER2 with HLX22 (a novel HER2-specific antibody) with HLX02 (a trastuzumab biosimilar) and capecitabine/oxaliplatin chemotherapy. While the objective response and progression-free survival are encouraging, the future development of the combination in a crowded HER2 space remains unclear.

查看原文本刊更多论文

双重 HER2 抑制：两个比一个好吗？

Li等人展示了一项针对HER2+胃食管癌的随机前线II期试验的数据，该试验探索了HLX22（一种新型HER2特异性抗体）与HLX02（一种曲妥珠单抗生物类似物）和卡培他滨/奥沙利铂化疗双重靶向HER2。虽然客观反应和无进展生存期令人鼓舞，但在拥挤的 HER2 领域，该组合的未来发展仍不明朗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.